INVENTORY	12 Months Ended
Mar. 31, 2026
Inventory Disclosure [Abstract]
INVENTORY	NOTE 3- INVENTORY As of March 31, 2026, and March 31, 2025, inventory consisted of raw materials and finished goods. Given the nature of our pharmaceutical products, and the storage protocols associated with inventories compounding activities occur at the time of, or shortly before receipt of customer orders and shipment of finished goods. As of March 31, 2026, and 2025, the Company’s inventory consisted of raw materials totaling $612,824 and $411,810, respectively, and finished goods totaling $69,235 and $92,128, respectively.

The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 330
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/330/tableOfContent

Name:	us-gaap_InventoryDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration